Zobrazeno 1 - 10
of 197
pro vyhledávání: '"Combretastatin A-4 phosphate"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Toby Holmes, Joseph P. A. Harrity, Gillian M. Tozer, Marie Suggitt, Lucy Simpson, Chryso Kanthou, Lucy A Shaw, Andrew W. Brown
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
Combretastatin A-4 phosphate (CA4P) is a microtubule-disrupting tumour-selective vascular disrupting agent (VDA). CA4P activates the actin-regulating RhoA-GTPase/ ROCK pathway, which is required for full vascular disruption. While hypoxia renders tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cb3b0e798a3c56a9aebdb2f70aa5126
http://link.springer.com/article/10.1038/s41598-020-66568-8
http://link.springer.com/article/10.1038/s41598-020-66568-8
Autor:
Yicheng Ni, Sylvie Daminet, Emmelie Stock, Katrien Vanderperren, Matthijs Vynck, Ward De Spiegelaere, Hilde De Rooster, Kaat De Clercq, E. Abma, Leen Van Brantegem
Publikováno v:
SCIENTIFIC REPORTS
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports
Combretastatin A4-phosphate (CA4P) is an anti-vascular agent which selectively shuts down blood supply in tumours, resulting in extensive tumour necrosis. The aim of this study was to assess in vivo, non-invasive ultrasound techniques for the early e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f5f6e1ddc147a5253cfcac7692fd764
https://doi.org/10.1038/s41598-019-45682-2
https://doi.org/10.1038/s41598-019-45682-2
Publikováno v:
Research in Veterinary Science. 112:222-228
Combretastatin A-4 phosphate (CA4P) selectively blocks tumor blood flow. However, the detailed mechanisms through which CA4P specifically affects tumor blood vessels are not well understood. Recent reports revealed that tumor tissue-derived endotheli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfc644cc3cd6a381e5eb78d487d67f42
https://doi.org/10.1016/j.rvsc.2017.05.017
https://doi.org/10.1016/j.rvsc.2017.05.017
Publikováno v:
Biomedicine & Pharmacotherapy. 89:36-46
Tubulin targeting agents have received considerable interest as a potential tumor-selective vascular disrupting agents, which represent another avenue for cancer growing therapeutic opportunities. Hence, the present study was conducted to investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a9c3017f724e0c00ef6cbab5b45a181
https://doi.org/10.1016/j.biopha.2017.02.019
https://doi.org/10.1016/j.biopha.2017.02.019
Autor:
Junshuang Gao, Jixiang Cao, Jiebin Dong, Shixin Zhou, Hongkui Deng, Yun Bai, Jingjing Zhao, Changwen Deng
Publikováno v:
Mol Ther
Chimeric antigen receptor (CAR) T cell therapy remains relatively ineffective against solid tumors due to inadequate infiltration and in vivo expansion of CAR-T cells. Unlike hematological malignancies, solid tumors have vascular barriers that hinder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f81179179c291d913dc4399ef3e85a7
https://europepmc.org/articles/PMC6953963/
https://europepmc.org/articles/PMC6953963/
Publikováno v:
Cancer chemotherapy and pharmacology. 84(6)
Nanomedicines can generally only reach cancer cells at the edges of tumors, leaving most tumor cells in the central regions untreated. Previous studies showed that treatment with the vascular disrupting agent combretastatin-A4-phosphate (CA4P) can di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1c10824c1eb08a3f4cbec3164489a57
https://pubmed.ncbi.nlm.nih.gov/31520101
https://pubmed.ncbi.nlm.nih.gov/31520101
Publikováno v:
Cancer letters. 380(2):552-560
The greatest challenge in treating acute myeloid leukemia (AML) is refractory disease. With approximately 60-80% of AML patients dying of relapsed disease, there is an urgent need to define and target mechanisms of drug resistance. Unfortunately, tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___01423::8bb3d8827ff310dfc497ddbda4ceffb9
https://research.rug.nl/en/publications/da94a1ee-1282-43ae-8df8-7f9c53f2b813
https://research.rug.nl/en/publications/da94a1ee-1282-43ae-8df8-7f9c53f2b813
Autor:
Cuihua Jiang, Dongjian Zhang, Dejian Huang, Shaoli Song, Fei Peng, Jian Zhang, Qiaomei Jin, Cong Wang, Meng Gao, Jindian Li
Publikováno v:
Oncotarget
// Meng Gao 1, 2 , Dongjian Zhang 1, 2 , Qiaomei Jin 1, 2 , Cuihua Jiang 1, 2 , Cong Wang 3 , Jindian Li 3 , Fei Peng 1, 2 , Dejian Huang 1, 2 , Jian Zhang 1, 2 , Shaoli Song 4 1 Laboratory of Translational Medicine, Jiangsu Province Hospital of Inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acd2df5d2721ecedf6263ff8faa6a7de
https://doi.org/10.18632/oncotarget.11249
https://doi.org/10.18632/oncotarget.11249
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.